Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00807482 · ClinicalTrials.gov registry record
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease
A clinical trial of Kartagener Syndrome, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- 1,800
- Enrollment target
- 1
- Study location
NCT00807482 is a study of Kartagener Syndrome that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 1,800 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00807482, a study of Kartagener Syndrome, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- 1,800 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall short-term goals of this project include the following: 1) identify the genes that are key to the function of respiratory cilia to protect the normal lung; and 2) the effects of genetic mutations that adversely affect ciliary function and cause primary ciliary dyskinesia (PCD), which results in life-shortening lung disease. The long-term goal of this project is to develop better understanding of the underlying genetic variability that adversely modifies ciliary function, and predisposes to common airway diseases, such as asthma and chronic obstructive pulmonary disease.
Conditions Studied
Study Locations (1)
North Carolina
- The University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2004-01 |
| Est. Completion | 2027-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00807482
The ClinicalTrials.gov registry entry for NCT00807482 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kartagener Syndrome appearing as the primary indexed condition, and to 0 interventions.
NCT00807482 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT00807482 about?
NCT00807482 is a clinical study titled "Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease". The overall short-term goals of this project include the following: 1) identify the genes that are key to the function of respiratory cilia to protect the normal lung; and 2) the effects of genetic mutations that adversely affect ciliary function and cause primary ciliary dyskinesia (PCD), which res...
What is the current status of trial NCT00807482?
This trial is currently recruiting. The enrollment target is 1,800 participants. The study started on 2004-01. Estimated completion is 2027-04.
What conditions does trial NCT00807482 study?
This clinical trial studies the following conditions: Kartagener Syndrome.
Who is sponsoring clinical trial NCT00807482?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00807482 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kartagener Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.